ArticleOncology letters2020
Upregulation of
Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 15 citations in OpenAlex.
- Establishment of a Seven-Gene Signature Associated with CD8International journal of molecular sciences · 2023Trial
- MYBL2 impedes cisplatin sensitivity through suppressing GSDME-mediated pyroptosis in lung adenocarcinoma.Cell death discovery · 2026Article
- Integrative Machine Learning and Experimental Validation Identify MYBL2 as a Prognostic Biomarker and Therapeutic Target in Hepatocellular Carcinoma.Oncology research · 2026Article
- Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia.Cell death discovery · 2025Article
- Clinical Significance of MYBL2 Expression in Hepatocellular Carcinoma: Impact on Overall Survival.OncoTargets and therapy · 2025Article
- Alteration of chromatin states perturb the transcription regulation of gene during hydronephrosis.Frontiers in genetics · 2025Article
- Genome-Wide CRISPR Screen Identifies Genes Involved in Metastasis of Pancreatic Ductal Adenocarcinoma.Cancers · 2024Article
- Avian Models for Human Carcinogenesis-Recent Findings from Molecular and Clinical Research.Cells · 2024Review
- A-MYB substitutes for B-MYB in activating cell cycle genes and in stimulating proliferation.Nucleic acids research · 2024Article
- Article
- Article
- [High expression of MYBL2 promotes progression and predicts a poor survival outcome of prostate cancer].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- MYBL2 accelerates epithelial-mesenchymal transition and hepatoblastoma metastasis via the Smad/SNAI1 pathway.American journal of cancer research · 2022Article
- MYB oncoproteins: emerging players and potential therapeutic targets in human cancer.Oncogenesis · 2021Review
- B-MYB-p53-related relevant regulator for the progression of clear cell renal cell carcinoma.Journal of cancer research and clinical oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MYB protooncogene-like 2 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.